SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy’s loses appeal for Lunesta patent case in U.S: Report

27 Sep 2013 Evaluate

Dainippon Sumitomo Pharma's Sunovion, reportedly has won an U.S appeals court ruling that Dr Reddy's Laboratories' generic version of sleep aid ‘Lunesta’ would breach a patent that expires next year. Further, US Court of Appeals for the Federal Circuit in Washington reportedly opined that there was an error in ruling by the trial Judge who viewed that Dr. Reddy’s version did not infringe the patent. Lunesta generated $136 million in sales during the first quarter in North America and China.

With this development, the company has reached settlements with other companies over the sleep medicine, including one with Teva Pharmaceutical Industries that enable low-cost versions to enter the market before the patent expires.

Dr Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1279.70 -13.55 (-1.05%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×